GSK surrenders HSV vaccine hopes after phase 2 fail, ceding race to Moderna, BioNTech
GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the likes of Moderna and BioNTech.
All Posts in "News Team"
Gilead inks $35M collab with AI drug discovery outfit Genesis
Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences.
Johnson & Johnson consolidates medtech brands under single banner
Johnson & Johnson is collating its pantheon of medtech brands under a single banner, to further simplify the company’s presentation.
With $3B funding round, Bain set to make more biotech bets
With a strong track record for identifying diamonds in the rough, Bain Capital Life Sciences (BCLS) has become a powerful force in biotech investing, pulling in more funding for each of its big-money rounds.
Nasdaq Hits a Record as Wall Street Drifts Ahead of Federal Reserve’s Meeting
U.S. stock indexes drifted through mixed trading ahead of a meeting by the Federal Reserve later this week that could set Wall Street’s direction into next year
Japan’s SoftBank Plans to Invest $100 Billion in US Projects Over the Next Four Years.
President-elect Donald Trump joined SoftBank Group CEO Masayoshi Son to announce plans by the Japanese company to invest $100 billion in U.S. projects over the next four years
Federal Reserve Is Likely to Slow Its Rate Cuts With Inflation Pressures Still Elevated
Americans hoping for lower borrowing costs for homes, credit cards and cars may be disappointed after this week’s Federal Reserve meeting
Wall Street Ends Mixed After a Bumpy Week
Stock indexes closed mixed on Wall Street at the end of a rare bumpy week
Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med
Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug.
AstraZeneca, Daiichi unpack Dato-DXd’s overall survival fail ahead of FDA decision
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in non-small cell lung cancer (NSCLC), extending the list of molecules that have fallen short in head-to-head fights with docetaxel.
Weekly Market Review – December 21, 2024
Weekly Market Review – December 21, 2024
Medtronic appoints new chief medical officer for digital surgery and robotics
Neurocrine’s bid to save schizophrenia prospect fails
FDA greenlights over-the-counter hearing aid features for Apple’s AirPods
Oncternal folds all clinical trials after lackluster data drop, patient death
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs
FDA pushed to be more open, collaborative to accelerate rare disease R&D
In wake of Q2 revenue drop, Charles River cuts 3% of workforce
Inflammatix collects $57M as it awaits FDA review of infectious disease test